Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Galera Therapeutics shares are trading lower by 34.8% during Monday's session. The company said its shares will be delisted due to non-compliance with Nasdaq's continued listing standards.
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
Shares of Doma Holdings Inc. (NYSEDOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
Shares of TransMedics Group, Inc. (NASDAQTMDX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.
The Dow Jones index closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
